Peaks from CD34+/monocyte-derived brain myeloid cells showed preferential enrichment for risk loci associated with multiple sclerosis, Alzheimer’s disease, intellectual disability, and depression in comparison to iHPCs peaks (Fig. 5l). This evidence concerns the gene CD34 and depressive symptom measurement.